Testimony: High Drug Prices Have ‘Enormous Human Cost’

Executives from Valeant Pharmaceuticals testified before a Senate committee Wednesday regarding the company’s pricing practices. A U-M physician told his patients’ side of the story.

4:00 PM

Author | Shantell M. Kirkendoll

A lucrative pricing strategy for pharmaceutical companies has increased the workload for doctors — and the burden for patients.

Fred Askari, M.D., Ph.D., for example, is using more clinic staff time to help patients figure out how to manage 3,000 percent price increases on their prescriptions, a change he says is not without consequences.

Askari testified Wednesday before lawmakers on Capitol Hill as the U.S. Senate Committee on Aging focuses on the pharmaceutical company Valeant's practice of buying smaller drug companies with specialized niche drugs and jacking up prices. It's a trend reflected across the pharmaceutical industry.

One Valeant-owned drug in particular, Cuprimine, which is taken by the Wilson disease patients Askari treats at the University of Michigan Health System, rose from $888 for 100 capsules to $26,189 for 100 after Valeant bought the rights to sell it in 2010.

"One should not confuse companies which institute sudden and dramatic price increases on long-standing critical drugs with those which are truly developing new ones," says Askari, associate professor of hepatology at the University of Michigan.

Heart drugs have also had huge price increases. "There is an enormous human cost associated with these practices," says Askari.

The persistently increasing price of Valeant's Wilson disease drugs poses a problem for up to half of my patients.
Fred Askari, M.D., Ph.D.

Access to necessary treatments

After arriving at a diagnosis of Wilson disease, an inherited disorder of copper processing, the good news is it's manageable with proper treatment. In people with Wilson disease, copper overwhelms the body, chiefly damaging the liver and brain.

Patients take drugs such as Cuprimine, which has been used to treat Wilson disease since 1956, and Syprine, both sold by Valeant, for life to remove excess copper in their body.

Risks of not treating Wilson disease or gaps in treatment include liver failure, brain damage and death.

But as prices rise, Askari says he's seeing more patients hoard pills or skip doses to stretch out their supply in case they lose access. Patients have also sought his clinic's help in applying for patient assistance programs.

"I have worked with dozens of patients to obtain Syprine through Valeant's patient assistance program. It is time-consuming and frustrating," says Askari, who treats about 400 Wilson disease patients annually and consults on dozens of other cases.

"Even when patients are approved for patient assistance, they cannot be certain that they can stay in the program. They have to reapply every year."

And they can't always do it on their own. Some patients with Wilson disease have neurological conditions, which can make it even more difficult for them to navigate the assistance programs.

"The persistently increasing price of Valeant's Wilson disease drugs poses a problem for up to half of my patients," he told lawmakers. "One patient was denied coverage and left off treatment completely for several weeks. Access to appropriate treatment is especially a problem for seniors with Medicare."

He urged Congress to arrive at policies that protect patients while maintaining incentives for lifesaving therapies.

"Ethical pharmaceutical companies do support research, which provides new and improved treatments for diseases," he says. "Wilson patients have many unmet needs with current treatments."

Based on an expectation of reasonable investment returns, companies invest in developing these new treatments, such as gene therapy, once-daily dosing regimens, and novel therapies such as one being investigated, tetrathiomolybdate anticopper therapy, which offers hope for improved neurological outcomes.

"We are fortunate that there are companies which safely manufacture, test and distribute medications for rare diseases," Askari says.

Also on Wednesday, the chief executive of Valeant testified before the Senate committee, calling the company's aggressive drug-pricing policy "a mistake."


More Articles About: Industry DX Wilsons Disease Liver Conditions & Procedures
Health Lab word mark overlaying blue cells
Health Lab

Explore a variety of healthcare news & stories by visiting the Health Lab home page for more articles.

Media Contact Public Relations

Department of Communication at Michigan Medicine

[email protected]

734-764-2220

Stay Informed

Want top health & research news weekly? Sign up for Health Lab’s newsletters today!

Subscribe
Featured News & Stories Image of woman with scientific objects, focusing on insulin resistance
Health Lab
Large genetic study reveals causes for insulin resistance, metabolic syndrome
Study uncovers genetic components of insulin resistance.
human-internal-liver-drawing-white
Health Lab
How using new organ storage technology can improve liver transplantations
The process, also known as liver perfusion, works differently than traditional ischemic cold storage methods for donor livers by involving technology that recreates the optimal physiological conditions for the organ.
cells in green and purple and black background under microscope
Health Lab
Tiny model organs detect liver toxicity of new drugs
A University of Michigan-led study provided evidence of the efficacy of a new drug-induced liver injury screening platform using human liver organoids, or tiny 3D models of organs developed from patients’ stem cells that grow in petri dishes.
surgeons in operating room
Health Lab
A unique approach to transplantation for liver malignancies
A Michigan Medicine transplant specialist examines different ways of caring for patients with liver cancer.
liver in bright green against navy background
Health Lab
Genetic variation with MASLD reveals subtypes and potential therapeutic avenues
A Michigan Medicine team of experts seeks to identify the human genetic causes of MASLD, formerly called NAFLD
black male in hospital bed smiling
Health Lab
There’s hope for patients living with cirrhosis
Liver specialists at Michigan Medicine examine the state of the art for the diagnosis and management of the chronic liver disease.